Do Cancer Drugs Trigger Skin Issues?
November 26, 2024
-
2 min
5 Key Takeaways
-
1
Nearly 50% of significant dermatologic adverse events associated with anticancer therapies are linked to targeted therapies.
-
2
Rash, dry skin, alopecia, and inflammatory conditions were the most frequently reported adverse events.
-
3
Enfortumab vedotin, a newer therapy, showed a notable percentage of skin-related adverse events.
-
4
The study was published in the Journal of the American Academy of Dermatology.
-
5
Fisher’s exact test and the Bonferroni correction were employed to ensure statistical validity.
The Food and Drug Administration's Adverse Event Reporting System revealed that approximately 50% of significant dermatologic adverse events associated with anticancer therapies are linked to targeted therapies. The study, encompassing over 3 million reports, highlighted the most frequently reported adverse events, including rash, dry skin, alopecia, and inflammatory conditions. Additionally, newer therapies like enfortumab vedotin showed a notable percentage of skin-related adverse events. The findings, published in the Journal of the American Academy of Dermatology, underscore the importance of monitoring dermatologic adverse events to enhance clinical decision-making and post-marketing surveillance.
Listen Tab content
